These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 20583848)

  • 1. Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms.
    Archer DF
    Drugs Aging; 2010 Jul; 27(7):533-44. PubMed ID: 20583848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S; Komm BS
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
    Komm BS; Mirkin S; Jenkins SN
    Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ; Gillespie JA
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating menopausal symptoms with a tissue-selective estrogen complex.
    Levine JP
    Gend Med; 2011 Apr; 8(2):57-68. PubMed ID: 21536225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture.
    Rossini M; Lello S; Sblendorio I; Viapiana O; Fracassi E; Adami S; Gatti D
    Drug Des Devel Ther; 2013; 7():601-10. PubMed ID: 23901263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes.
    Smith CL; Santen RJ; Komm B; Mirkin S
    Breast Cancer Res; 2014 Jun; 16(3):212. PubMed ID: 25928299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.
    Pinkerton JV; Komm BS; Mirkin S
    Climacteric; 2013 Dec; 16(6):618-28. PubMed ID: 23805785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women.
    Palacios S; Mejía Ríos A
    Drugs Today (Barc); 2015 Feb; 51(2):107-16. PubMed ID: 25756066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in menopausal therapy: the tissue-selective estrogen complex.
    Moore A
    J Am Assoc Nurse Pract; 2013 Mar; 25(3):126-33. PubMed ID: 24218199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
    Kagan R
    J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue selective estrogen complex (TSEC): a review.
    Pickar JH; Boucher M; Morgenstern D
    Menopause; 2018 Sep; 25(9):1033-1045. PubMed ID: 29533367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE).
    Lindsay R
    Osteoporos Int; 2011 Feb; 22(2):447-51. PubMed ID: 21069294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
    Palacios S; Currie H; Mikkola TS; Dragon E
    Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of SERMs for treatment in postmenopausal women.
    Pinkerton JV; Thomas S
    J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy.
    Sharifi M; Lewiecki EM
    Expert Rev Clin Pharmacol; 2014 May; 7(3):281-91. PubMed ID: 24580081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.
    Lobo RA; Pinkerton JV; Gass MLS; Dorin MH; Ronkin S; Pickar JH; Constantine G
    Fertil Steril; 2009 Sep; 92(3):1025-1038. PubMed ID: 19635615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
    Pinkerton JV; Stovall DW
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What do TSECs provide in the menopausal hormone therapy?
    Llaneza P; Calaf J; Jurado AR; Mendoza N; Otero B; Quereda F; Sánchez-Borrego R; Lubian D
    Gynecol Endocrinol; 2018 Oct; 34(10):826-832. PubMed ID: 29790381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.